Ginkgo Bioworks

Ginkgo Bioworks reported Q2 2026 revenue of $20 million, missing the consensus estimate of $29.9 million; revenue thus fell 48% year over year. Adjusted EPS of -$0.92 beat expectations but could not offset the negative market reaction, and the stock fell about 4.9% after the close. The company emphasizes its focus on autonomous labs, reports total liquidity of $389 million and confirms a 2026 cash burn guidance of $125–150 million. » Más en de.investing.com

Ginkgo Bioworks has introduced the Ginkgo Cloud Lab platform, a web-based interface for remote access to its modular, robot-assisted lab infrastructure with over 70 instruments. The platform uses reconfigurable automation carts, maglev tracks and an AI agent called EstiMate that reviews protocols written in natural language and provides pricing and compatibility information. The rollout is intended as part of the 2026 strategy to shift research and development services to the autonomous lab Nebula and to replace traditional lab benches with robotic infrastructure. The stock faces short-term headwinds after recent price losses, but analysts currently consider it undervalued. » Más en de.investing.com

Ginkgo Bioworks and Invaio Sciences have agreed a partnership to develop microbial strains for the industrial production of peptide-based crop protection solutions. Ginkgo will deploy its platform, genetically engineered strains and autonomous lab infrastructure to scale Invaio’s fermentation processes and production targets. The aim is to make peptides available as a biological alternative to conventional pesticides against resistant pests. With this, Ginkgo is focusing on support from strain development through bioprocess development for agricultural solutions. » Más en de.investing.com

Ginkgo Bioworks reports that its autonomous lab, driven by OpenAI’s GPT-5, has reduced the cost of cell-free protein synthesis by 40% versus prior benchmarks. The system ran more than 36,000 experiments across six iterative cycles and achieved production costs of $422 per gram compared with $698 previously. The AI-powered platform generated nearly 150,000 experimental data points with minimal human intervention; Ginkgo is already selling the improved reaction mix through its reagents shop and is releasing the Pydantic model used for validation as open source. » Más en de.investing.com

Ginkgo Bioworks is reorganizing operational responsibility effective January 1, 2026: Dr. Reshma Shetty will remain president and board member, hand COO duties to Jennifer Wipf and delegate strategic-operational management to CEO Dr. Jason Kelly. Wipf will take over daily commercial operations, procurement, resource and facility management, and HR, and will report to Dr. Kelly. The company faces difficult market conditions with a valuation of roughly $494 million and has recently lost nearly 25% of its value, while also reporting new contracts and collaborations, including an up-to-$47 million contract with the Pacific Northwest National Laboratory and several ARPA-H partnerships. » Más en de.investing.com